KM Research Hub
← 返回论文库
已完成 入排:排除 图源:可得 入排置信度 0.96

Cemiplimab monotherapy as first-line treatment of patients with brain metastases from advanced non-small cell lung cancer with programmed cell death-ligand 1 ≥50.

Saadettin Kilickap, Mustafa Özgüroğlu, Ahmet Sezer, Mahmut Gümüş, Igor Bondarenko, Miranda Gogishvili, Haci M Turk, Irfan Cicin, Dmitry Bentsion, Oleg Gladkov, Virote Sriuranpong, Ruben G W Quek, Debra A G McIntyre, Xuanyao He, Jennifer McGinniss, Frank Seebach, Giuseppe Gullo, Petra Rietschel, Jean-Francois Pouliot

Cancer 131(10) e35864

PMID40323717
PMCIDPMC12051739
DOI10.1002/cncr.35864
发表日期2025-05-05
入排依据:属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
摘要

摘要

BACKGROUND: In the phase 3 EMPOWER-Lung 1 study, first-line cemiplimab monotherapy provided significant survival benefit versus chemotherapy in patients with advanced non-small cell lung cancer (NSCLC) with programmed cell death-ligand 1 (PD-L1) ≥50%. This exploratory subgroup analysis investigated the clinical outcomes of cemiplimab treatment in patients with advanced NSCLC with brain metastases. METHODS: Patients with advanced NSCLC were randomized (1:1) to cemiplimab 350 mg every 3 weeks or four cycles of platinum doublet chemotherapy (NCT03088540). Patients with symptomatic radiotherapy-treated brain metastases were eligible to enroll. Of the 565 patients with confirmed PD-L1 expression ≥50%, 69 (12%) had brain metastases at baseline. RESULTS: Patients with brain metastases who received cemiplimab had a median overall survival (OS) of 52.4 months compared with 20.7 months for those who received chemotherapy (hazard ratio [HR], 0.40; p = .0031) and a median progression-free survival (PFS) of 12.5 versus 5.3 months (HR, 0.33; p = .0002), respectively. Patients without brain metastases had a median OS of 24.3 months with cemiplimab versus 12.5 months with chemotherapy (HR, 0.63; p < .0001); their median PFS was 6.5 months versus 5.2 months (HR, 0.55; p < .0001), respectively. Cemiplimab was associated with a significant improvement in global health status/quality of life in all patients, including those with brain metastases. The cemiplimab safety profile was generally similar in all patients. CONCLUSIONS: In patients with advanced NSCLC with PD-L1 ≥50%, first-line cemiplimab monotherapy improved survival and patient-reported outcomes over chemotherapy for those who received prior radiotherapy for symptomatic brain metastases.

KM 提取结果

2 个 Figure · 4 个 KM 面板

进入结果中心
KM Figure2 个面板

FIGURE 1

FIGURE 1 Kaplan–Meier curves showing OS by the independent review committee in patients (A) with and (B) without brain metastases at baseline. Patients were stratified by tumor histology, with HR based on a stratified Cox regression model using the treatment as a covariate and tumor histology as a stratification factor. p values are two‐sided. CI indicates confidence interval; HR, hazard ratio; mOS, median overall survival; NE, not evaluable; OS, overall survival.

A

OS

FIGURE 1 · Panel A

complete 待 EXE 对齐 预期 2 条 已提取 2 条

Panel A 是同一 FIGURE 1 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

查看结果
B

OS

FIGURE 1 · Panel B

complete 待 EXE 对齐 预期 2 条 已提取 2 条

Panel B 是同一 FIGURE 1 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

查看结果
KM Figure2 个面板

FIGURE 2

FIGURE 2 Kaplan–Meier curves showing PFS by the independent review committee in patients (A) with and (B) without brain metastases at baseline. Patients were stratified by tumor histology, with HR based on a stratified Cox regression model using the treatment as a covariate and tumor histology as a stratification factor. p values are two‐sided. CI indicates confidence interval; HR, hazard ratio; NE, not evaluable; mPFS, median progression‐free survival; PFS, progression‐free survival.

A

PFS

FIGURE 2 · Panel A

complete 待 EXE 对齐 预期 2 条 已提取 2 条

Panel A 是同一 FIGURE 2 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

查看结果
B

PFS

FIGURE 2 · Panel B

complete 待 EXE 对齐 预期 2 条 已提取 2 条

Panel B 是同一 FIGURE 2 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

查看结果
其他 Figure(1,默认折叠)

这些图片未产生 KM 曲线结果,不在主页面重复展示。

FIGURE 3FIGURE 3 Forest plot model of estimated between‐treatment differences (cemiplimab vs. chemotherapy) in overall change from baseline (MMRM model) in patients with brain metastases at baseline per (A) EORTC QLQ‐C30 GHS/QoL and functional scales, (B) EORTC QLQ‐C30 symptom scales, and (C) EORTC QLQ‐LC13 symptom scales. CI indicates confidence interval; EORTC, European Organization for Research and Treatment of Cancer; GHS, global health status; LC, lung cancer; LS, least‐squares; MMRM, mixed‐model with repeated measures; QLQ‐C30, Quality of Life‐Core 30; QLQ‐LC13, Quality of Life‐Lung Cancer Module; QoL, quality of life; SE, standard error.
非 KM Figure